

Special Issue

Targeting Proline Metabolic Pathway for Regulation of Apoptosis/Autophagy in Cancer

Message from the Guest Editor

Proline metabolism involves glutamate and ornithine, and enzymatic activity of proline oxidase, Δ^1 -pyrroline-5-carboxylate (P5C) reductase, P5C dehydrogenase, P5C synthetase, and ornithine d-aminotransferase. The pathway is connected to other essential metabolic cycles: TCA, urea, and pentose phosphate pathway. Disorders in proline metabolism are linked to several diseases. Recent discoveries on the proline metabolism, enzymes involved in proline synthesis and catabolism indicate its important role in tumor growth and cancer progression. This Special Issue aims to cover the cutting-edge research activities and recent advancements in the area of proline metabolism pathways and factors regulating its activity as a molecular target for cancer treatment. I cordially invite you to publish your manuscripts in this *Pharmaceuticals* Special Issue, titled "Targeting Proline Metabolic Pathway for Regulation of Apoptosis/Autophagy in Cancer."

Guest Editor

Dr. Wojciech Miltik

Department of Analysis and Bioanalysis of Medicines, Medical University of Białystok, Białystok, Poland

Deadline for manuscript submissions

closed (25 November 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/59221

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)